Trial Profile
A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary) ; Dulaglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-D
- Sponsors Sanofi
- 20 Jul 2023 Primary endpoint has been met (Change From Baseline to Week 56 in HbA1c), according to Results published in the Diabetes, Obesity and Metabolism
- 20 Jul 2023 Results from three phase 3 studies: AMPLITUDE-D, AMPLITUDE-S, and AMPLITUDE-L reporting efficacy and safety data published in the Diabetes, Obesity and Metabolism
- 29 Apr 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.